Tissue Regenix Share Discussion Threads

[bamboo2] 30/4/2015 08:53

NHSBT Strategic Plan 2015-19 launched later today. We should get a mention.

----------------------------------------------------------------------------

Odell interviewed quite badly in the recent vid posted above.

When asked about competition, he said there were 16 competitors in the US, but failed to mention how Dermapure trumps most of these other products.

eg
Many of them are deep frozen rather than ambient products.
Others are derived from amniotic tissue rather than dermis.
Some feature 'added' third party stem cells and other cellular materials.

imo

[rayrac] 30/4/2015 07:28

Just keep in mind, that BTG, another company in a similar line of business and a market cap of £2.7billion, was but a few years ago, valued very much like TRX is now. I know that, because held the shares when they were below a £!😡

Hence I'm determined not to miss the boat a second time!

[rayrac] 29/4/2015 18:14

Ah, thanks iggy! It's rather late for me at my age, to be out that late at night. But I'll give it some thought.

[igbertsponk] 29/4/2015 17:15

Rayrac - obviously just by personal invite for serious investors only ;-)

DATE: Thursday 14th May 2015
TIME: 5:45pm arrival for a prompt 6:00pm start
VENUE: Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB
ROOM: Charles Suite (1st floor)

Details
Dear Investor

Our biotechnology forum on the 14th May brings together four very exciting companies.

Joining us are Epistem Holdings (AIM: EHP), Abzena (AIM:ABZA), ValiRx (AIM:VAL) & Tissue Regenix (AIM:TRX).

Epistem is fresh from announcing that it has been given the go-ahead to distribute its flagship diagnostic test for TB in India where there are 2 million new cases of the disease each year.

Abzena earlier this month announced that two of its partners have entered clinical development on products using its own technology.

ValiRx has recently announced that its lead drug VAL201 - a treatment for prostate cancer among other conditions - passed first patient dosing in its ongoing phase II trial.

Meanwhile, Tissue Regenix has this week recieved the green light to start clinical trials of Orthapure XT, a device for the reconstruction of a torn anterior cruciate ligament.

Sign up early because places are limited. Each company will pitch its unique investment story and management will be available afterwards for questions over drinks and canapés.

Epistem Holdings (AIM:EHP) is an established biotechnology company with headquarters in Manchester and facilities in the US. Epistem's current market capitalisation is £32 million.

The company has now evolved into a dynamic and successful enterprise enabling advances in medicine through the provision of innovative services.

The company's latest success has seen its application to distribute its flagship TB testing product in India aprooved.

Chief Executive Matthew Walls will be at the forum on the 14th May to update investors on the company's future plans for growth.

Abzena (AIM:ABZA) provides a range of services and technologies to improve the chances of the successful development of therapeutic proteins and antibodies.

The company, which is currently valued by the market at £82 million, generates growing revenues from its services business and is poised for significant future growth through royalty bearing licences.

The demand for Abzena's services was recently underlined by the fact that two of its partners have entered clinical trials on products with the help of Abzena's technology.

CEO John Burt will be at the biotech forum to explain Abzena's story in more detail.

ValiRx (AIM: VAL) is focussed on the treatment of cancer, specialising in genetic analysis. Currently, the company has a market capitalisation of £7.5 million.

The drug developer recognises that there is a high demand for new personalised medicines and is positioned to capitalise on this.

Ongoing clinical trials on Valirx's flagship VAL201 candidate are progressing well, with recent tests showing that the drug is safe at doses which were tested.

CEO Satu Vainikka will be presenting at the event and updating investors on developments at the company.

Tissue Regenix (AIM:TRX) is an international medical devices company which develops products which are used to make replacement body parts using biological materials. The current market capitalisation is £123 million.

The potential applications of its technology are broad and could address critical clinical needs such as wound care, heart valve replacement and knee repair.

Meanwhile, Tissue Regenix has this week recieved the green light to start clinical trials of Orthapure XT, a device used for the reconstruction of a torn anterior cruciate ligament.

CEO Antony Odell will be present to explain the significance of this approval as well other developments.

Please turn up at 5:45pm to get yourself a seat and to allow for a prompt 6:00pm start. Each company has approximately 20 minutes to give a short presentation, followed by 10 minutes of Q&A.

We also have raffle where six lucky guests will each win a bottle of champers.
The evening will end with a complimentary bar and canapes, giving you the opportunity to speak with the directors and other investors.

[rayrac] 29/4/2015 17:12

Slightly disappointing end too the day? But hey ho, 27m shares might be giving a hint of things to come.

Iggy, I can't find mention of the proactive presentation on their site. What time is it and where is it?

Thanks

[rayrac] 29/4/2015 16:29

I might have a look at proactive and TRX. Just got to check I'm clear on the 14th!

[igbertsponk] 29/4/2015 14:24

No idea, but will be enough to trigger an RNS in due course.

[rayrac] 29/4/2015 13:05

Who did that? 26m traded in what looks like buy territory and probably made the share price jump just now!

[igbertsponk] 29/4/2015 13:03

TRX presenting at Proactive event on 14th May. I may well pop along.

[proactivest] 29/4/2015 12:07

Video interview with CEO Anthony Odell



Antony Odell, chief executive of Tissue Regenix (LON:TRX), discusses the company’s commercialisation push for its advanced wound care product.
Today, the AIM-listed group revealed it will be sharing the latest data on DermaPure with some of the industry’s leadingprofessionals at the Symposium for Advanced Wound Care’s spring meeting in the US.
It follows the news of a ‘critical step’ towards regulatory sign-off for the start of clinical trials for Orthopure XT, a decellularised tendon device for the reconstruction of a torn anterior cruciate ligament – a career-threatening injury for footballers and other athletes.

[luminoso] 29/4/2015 11:05

Bamboo. There's nothing to stop them publishing some sales figures from the post results period, surely.

[luminoso] 29/4/2015 11:02

12.9cm2 - thats a big wound to be healed in 6.5 weeks average ! Agree with Iggy that the success of the product warrants a big splash of publicity. Maybe it will follow soon.

[igbertsponk] 29/4/2015 10:23

Don't get me wrong, I'm not stressed or unhappy. Just a tad impatient !
And all my shares (this is only a few percent of my portfolio) are held at a good profit, and in CGT free wrappers.

[bamboo2] 29/4/2015 10:22

The results due a week on Monday [11 May], only include figures up until 31 Jan 2015. I doubt there will be very much on the income side at this stage.

I guess this will only start to bear fruit as experience of the product is gained at clinic and hospital level.

[rayrac] 29/4/2015 10:13

In the results perhaps? Can't see them rns-ing that kind of info.

Patience could be the reward. Don't let holding so many shares stress you out!😰

I don't. 😇

[igbertsponk] 29/4/2015 09:58

I want to see this as an RNS. And was hoping that we'd be there by now - what are all those US salesmen doing ??
"A review of the first 1,000 SOLD showed a 90% first time cure rate, and a further 9% were cured with a second treatment".

[igbertsponk] 29/4/2015 09:13

But seems only one patient needed additional treatment - average of 1.1 treatments over 10 patients.

[bamboo2] 29/4/2015 09:04

Ig, what's different about this case study is that it seems additional treatment has been given where neccesary to ensure the 100% cure rate. This extra care didn't occur in the phase three trial. Phase three was evaluating the effect of one treatment.

This phase four trial is about fine tuning the treatment, rather than proving it works.

[igbertsponk] 29/4/2015 08:49

Indeed Bamboo, but I wish they'd get a wiggle on.
Can't help thinking that one newspaper article "Wonder patch cures 100% of all sores" would get all the patients demanding them off their docs. As the docs seem to be rather slow on the uptake - they probably make more money from repeat treatments of the things that don't work !

[bamboo2] 29/4/2015 08:46

Ig, this is an interim trial result rather than the whole multi-center trial.

The multi-center phase four trial is not yet completed.

I think it reports early findings in June.

[rayrac] 29/4/2015 08:16

Yes bam, 100%!

Thanks much.😃

[bamboo2] 29/4/2015 07:47

Read it again. That's 100%.

The presentation takes place in the morning of Friday May 1st.